SCHEMBL332633

SCHEMBL332633

CC1CCCC(C)CCC(C(C)C)CC1

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.34
TRPM8 Q7Z2W7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1164447 1.00 TRPA1 (0.34) TRPA1TRPM8
SCHEMBL29350756 1.00 TRPA1 (0.34) TRPA1TRPM8
SCHEMBL7979 0.91 TRPA1 (0.39) TRPA1TRPM8
SCHEMBL1760669 0.91 TRPA1 (0.39) TRPA1TRPM8
SCHEMBL452781 0.91 TRPA1 (0.39) TRPA1TRPM8
Hydrochloric Acid SCHEMBL6863594 0.88 TRPA1 (0.37) TRPA1TRPM8
Ammonia Solution, Strong SCHEMBL5944185 0.88 TRPA1 (0.37) TRPA1TRPM8
Charcoal, Activated SCHEMBL4530459 0.88 TRPA1 (0.37) TRPA1TRPM8
Water SCHEMBL2851760 0.88 TRPA1 (0.37) TRPA1TRPM8
SCHEMBL38654752 0.88 TRPA1 (0.37) TRPA1TRPM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250177456-A1 METHOD AND COMPOSITION FOR PREVENTING AND/OR TREATING METABOLIC DISORDERS UNIV SHANDONG (CN) 2025-06-05 US disclosed
US-20240417261-A1 SINGLE WALLED CARBON NANOTUBE-BASED SLURRY FOR IMPROVED NUCLEAR FUEL CLADDING COATINGS AND METHOD OF FABRICATION OF SAME ATOMIC ENERGY OF CANADA LIMITED/ÉNERGIE ATOMIQUE DU CANADA LIMITÉE (CA) 2024-12-19 US disclosed
US-11932540-B2 Single walled carbon nanotube-based slurry for improved nuclear fuel cladding coatings and method of fabrication of same ATOMIC ENERGY OF CANADA LIMITED/ÈNERGIE ATOMIQUE DU CANADA LIMITÈE (CA) 2024-03-19 US disclosed
US-11851602-B2 Epoxide and fluorinated epoxide stabilizers for fluoroolefins THE CHEMOURS COMPANY FC, LLC (US) 2023-12-26 US disclosed
US-20210380859-A1 EPOXIDE AND FLUORINATED EPOXIDE STABILIZERS FOR FLUOROOLEFINS THE CHEMOURS COMPANY FC, LLC (US) 2021-12-09 US disclosed
US-20210355360-A1 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF THE CHEMOURS COMPANY FC, LLC (US) 2021-11-18 US disclosed
US-11130894-B2 Epoxide and fluorinated epoxide stabilizers for fluoroolefins THE CHEMOURS COMPANY FC, LLC (US) 2021-09-28 US disclosed
US-11124685-B2 Compositions comprising fluoroolefins and uses thereof THE CHEMOURS COMPANY FC, LLC (US) 2021-09-21 US disclosed
US-20210207014-A1 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF THE CHEMOURS COMPANY FC, LLC (US) 2021-07-08 US disclosed
US-11046877-B1 Compositions comprising fluoroolefins and uses thereof THE CHEMOURS COMPANY FC, LLC (US) 2021-06-29 US disclosed
US-20070108403-A1 refrigerants as heat exchanger; comprising 1,1,1,4,4,5,5,5-octafluoro-2-pentene mixture E. I. DU PONT DE NEMOURS AND COMPANY 2007-05-17 US disclosed
WO-2007053697-A2 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF E. I. DU PONT DE NEMOURS AND COMPANY (US) 2007-05-10 WO disclosed
EP-1353926-B1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES SOD CONSEILS RECH APPLIC (FR) 2006-03-08 EP disclosed
US-6887869-B2 Mikanolide derivatives, their preparation and therapeutic uses SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2005-05-03 US disclosed
EP-1438039-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-21 EP disclosed
US-20040138245-A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-07-15 US disclosed
US-20040122084-A1 Mikanolide derivatives, their preparation and therapeutic uses IPSEN PHARMA S.A.S. (FR) 2004-06-24 US disclosed
EP-1353926-A1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2003-10-22 EP disclosed
WO-2002096348-A2 PRODUCT COMPRISING MIKANOLIDE, DIHYDROMIKANOLIDE OR AN ANALOGUE THEREOF COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN CANCER TREATMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-12-05 WO disclosed
WO-2002055523-A1 MIKANOLIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250177456-A1 METHOD AND COMPOSITION FOR PREVENTING AND/OR TREATING METABOLIC DISORDERS LIPC, GYS2, PNLIP TRPA1 4441/4885TRPM8 4240/4885
US-20210355360-A1 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF GFPT1, PFAS, TRMT1 TRPA1 306/4885TRPM8 2387/4885
US-20040122084-A1 Mikanolide derivatives, their preparation and therapeutic uses MSR1, GSR, OGFR TRPA1 4685/4885TRPM8 3381/4885
US-20040138245-A1 Product comprising mikanolide, dihydromikanolide or an analogue thereof combine with another anti-cancer agent for therapeutic use in cancer treatment DTYMK, DGKG, DGKZ TRPA1 3308/4885TRPM8 1398/4885
US-11046877-B1 Compositions comprising fluoroolefins and uses thereof GFPT1, PFAS, TRMT1 TRPA1 306/4885TRPM8 2387/4885
US-20210207014-A1 COMPOSITIONS COMPRISING FLUOROOLEFINS AND USES THEREOF GFPT1, PFAS, TRMT1 TRPA1 306/4885TRPM8 2387/4885
US-11124685-B2 Compositions comprising fluoroolefins and uses thereof GFPT1, PFAS, TRMT1 TRPA1 306/4885TRPM8 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.